在患有心脏或肺部疾病的儿童中，在 RSV 季节 2 之前重新给予 Nirsevimab 的安全性。
Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease.
机构信息
Department of Pediatrics, SUNY Upstate Medical University, Syracuse, New York, USA.
Vaccines & Immune Therapies, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
出版信息
J Pediatric Infect Dis Soc. 2023 Aug 31;12(8):477-480. doi: 10.1093/jpids/piad052.
Abstract
In children with congenital heart disease and/or chronic lung disease entering their second respiratory syncytial virus (RSV) season, 200 mg nirsevimab had a similar safety profile to that of palivizumab and resulted in nirsevimab serum exposures associated with efficacy in healthy infants, supporting efficacy in this population at risk of severe RSV disease.
摘要
对于进入第二个呼吸道合胞病毒（RSV）流行季的患有先天性心脏病和/或慢性肺部疾病的儿童，200 毫克尼塞利珠单抗的安全性与帕利珠单抗相似，并且产生了与健康婴儿疗效相关的尼塞利珠单抗血清暴露，支持该高危 RSV 疾病人群的疗效。
相似文献
1
Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease.
J Pediatric Infect Dis Soc. 2023 Aug 31;12(8):477-480. doi: 10.1093/jpids/piad052.
2
Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.
Lancet Child Adolesc Health. 2023 Mar;7(3):180-189. doi: 10.1016/S2352-4642(22)00321-2. Epub 2023 Jan 9.
3
Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: An exploratory analysis of a phase 2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY).
Vaccine. 2024 Oct 24;42(24):126276. doi: 10.1016/j.vaccine.2024.126276. Epub 2024 Sep 5.
4
Balanced on the Biggest Wave: Nirsevimab for Newborns.
Neonatal Netw. 2024 Apr 1;43(2):105-115. doi: 10.1891/NN-2023-0056.
5
Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024.
MMWR Morb Mortal Wkly Rep. 2024 Mar 7;73(9):209-214. doi: 10.15585/mmwr.mm7309a4.
6
Nirsevimab Immunization to Prevent Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants and Children up to 24 Months of Age.
Nurs Womens Health. 2024 Feb;28(1):75-79. doi: 10.1016/j.nwh.2023.11.002. Epub 2023 Dec 6.
7
Nirsevimab for the prevention of respiratory syncytial virus disease in children. Statement of the Spanish Society of Paediatric Infectious Disease (SEIP).
An Pediatr (Engl Ed). 2023 Oct;99(4):257-263. doi: 10.1016/j.anpede.2023.09.006. Epub 2023 Sep 22.
8
Optimal Respiratory Syncytial Virus intervention programmes using Nirsevimab in England and Wales.
Vaccine. 2022 Nov 22;40(49):7151-7157. doi: 10.1016/j.vaccine.2022.10.041. Epub 2022 Oct 31.
9
Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.
N Engl J Med. 2020 Jul 30;383(5):415-425. doi: 10.1056/NEJMoa1913556.
10
Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV).
Expert Opin Investig Drugs. 2022 Jan;31(1):23-29. doi: 10.1080/13543784.2022.2020248. Epub 2021 Dec 28.
引用本文的文献
1
Estimating the economically justifiable price of nirsevimab versus standard of practice for the prevention of respiratory syncytial virus infections in neonates and infants in Spain: a cost-utility modelling study.
BMJ Public Health. 2025 Jul 31;3(2):e002441. doi: 10.1136/bmjph-2024-002441. eCollection 2025.
2
Systematic Review and Expert Consensus on the Use of Long-acting Monoclonal Antibodies for Prevention of Respiratory Syncytial Virus Disease: ARMADA (Advancing RSV Management And Disease Awareness) Taskforce.
Open Forum Infect Dis. 2025 Jul 2;12(7):ofaf396. doi: 10.1093/ofid/ofaf396. eCollection 2025 Jul.
3
RSV Hospital Admissions During the First 2 Seasons Among Children With Chronic Medical Conditions.
JAMA Netw Open. 2025 Jul 1;8(7):e2519410. doi: 10.1001/jamanetworkopen.2025.19410.
4
Post-Marketing Surveillance of Nirsevimab: Safety Profile and Adverse Event Analysis from Spain's 2023-2024 RSV Immunisation Campaign.
Vaccines (Basel). 2025 Jun 10;13(6):623. doi: 10.3390/vaccines13060623.
5
RSV: an overview of infection in adults.
Pneumonia (Nathan). 2025 Jun 25;17(1):15. doi: 10.1186/s41479-025-00165-z.
6
Cost-Effectiveness and Public Health Impact of Universal Prophylaxis with Nirsevimab Against Respiratory Syncytial Virus (RSV) Infections in all Infants in Japan.
Infect Dis Ther. 2025 Apr;14(4):847-865. doi: 10.1007/s40121-025-01134-1. Epub 2025 Mar 28.
7
A phase I, randomized, placebo-controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults.
Clin Transl Sci. 2025 Jan;18(1):e70095. doi: 10.1111/cts.70095.
8
[Not Available].
Can Fam Physician. 2024 Nov-Dec;70(11-12):e187-e191. doi: 10.46747/cfp.701112e187.
9
Approach to prevention of respiratory syncytial virus disease in infants by passive immunization.
Can Fam Physician. 2024 Nov-Dec;70(11-12):697-700. doi: 10.46747/cfp.701112697.
10
Nirsevimab to reduce infant morbidity from respiratory syncytial virus.
CMAJ. 2024 Sep 30;196(32):E1114-E1117. doi: 10.1503/cmaj.240780.
本文引用的文献
1
Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants.
N Engl J Med. 2023 Apr 20;388(16):1533-1534. doi: 10.1056/NEJMc2214773. Epub 2023 Apr 5.
2
Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.
Lancet Child Adolesc Health. 2023 Mar;7(3):180-189. doi: 10.1016/S2352-4642(22)00321-2. Epub 2023 Jan 9.
3
Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis.
Lancet. 2022 May 28;399(10340):2047-2064. doi: 10.1016/S0140-6736(22)00478-0. Epub 2022 May 19.
4
Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity.
N Engl J Med. 2022 Mar 3;386(9):892-894. doi: 10.1056/NEJMc2112186.
5
Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.
N Engl J Med. 2022 Mar 3;386(9):837-846. doi: 10.1056/NEJMoa2110275.
6
Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.
N Engl J Med. 2020 Jul 30;383(5):415-425. doi: 10.1056/NEJMoa1913556.
7
Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults.
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.01714-16. Print 2017 Mar.
8
Exposure Matching for Extrapolation of Efficacy in Pediatric Drug Development.
J Clin Pharmacol. 2016 Nov;56(11):1326-1334. doi: 10.1002/jcph.744.
Zotero 插件